The present invention relates to novel biheterocyclic derivatives which are factor Xa inhibitors; the pharmaceutically acceptable salts and N-oxides thereof; their uses as therapeutic agents and the methods of their making.
Design, synthesis, and structure–activity relationship study of novel plinabulin derivatives as anti-tumor agents based on the co-crystal structure
作者:Shixiao Wang、Changjiang Zhong、Feifei Li、Zhongpeng Ding、Yu Tang、Wenbao Li
DOI:10.1007/s11030-024-10835-7
日期:——
Plinabulin, a 2, 5-diketopiperazine-type tubulin inhibitor derived from marine natural products, is currently undergoing Phase III clinical trials for the treatment of non-small cell lung cancer (NSCLC) and chemotherapy-induced neutropenia (CIN). To obtain novel 2, 5-diketopiperazine derivatives with higher biological activity, we designed and synthesized two series of 37 plinabulinderivatives at
[EN] SUBSTITUTED AMIDINOARYL DERIVATIVES AND THEIR USE AS ANTICOAGULANTS<br/>[FR] DERIVES AMIDINOARYLE SUBSTITUES ET LEUR UTILISATION EN TANT QUE COAGULANTS
申请人:AXYS PHARMACEUTICALS, INC.
公开号:WO1999026941A1
公开(公告)日:1999-06-03
(EN) The present invention relates to novel biheterocyclic derivatives which are factor Xa inhibitors; the pharmaceutically acceptable salts and $i(N)-oxides thereof; their uses as therapeutic agents and the methods of their making.(FR) La présente invention concerne de nouveaux dérivés bihétérocycliques inhibiteurs du facteur Xa, leurs oxydes de $i(N) et leurs sels pharmaceutiquement acceptables, leurs utilisations en tant qu'agents thérapeutiques et leurs méthodes de production.